Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the Chinese National Medical Products Administration (NMPA)  formally known as the Chinese FDA, granted Sinovac Biotech…

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray…

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member of the company’s executive management team, with effect from April 1, 2021. Mrs. Nathalie Laarakker…

Intravacc announces formation of Scientific Advisory Board

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific Officer Virgil Schijns and further comprising scientific leaders in the fields of vaccinology, infectious diseases…

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek Bilthoven, the Netherlands, 19 februari 2021 – Intravacc, wereldwijd vooraanstaand op het gebied van translationeel onderzoek naar en de ontwikkeling van vaccins, maakt bekend dat haar nieuwe moderne pilot productiefabriek binnenkort in gebruik wordt genomen. Daarnaast geeft Intravacc leiding aan een consortium dat…

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement New state-of-the-art pilot vaccine production facility ready for use   Bilthoven, the Netherlands, 19 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that its new modern pilot production plant will soon be operational. In…

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV) vaccine Eupolio™, developed by Intravacc and out-licensed to South Korean LG Chem in 2014. The…

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than…